Crossmark

Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality

Crossref DOI link: https://doi.org/10.1186/s13293-021-00393-0

Published Online: 2021-09-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Laucyte-Cibulskiene, Agne http://orcid.org/0000-0003-4020-1467
Ward, Liam J. http://orcid.org/0000-0002-3320-1461
Ebert, Thomas

Tosti, Giulia

Tucci, Claudia

Hernandez, Leah

Kautzky-Willer, Alexandra

Herrero, Maria-Trinidad

Norris, Colleen M.

Pilote, Louise

Söderberg, Magnus

Brismar, Torkel B.

Ripsweden, Jonaz

Stenvinkel, Peter

Raparelli, Valeria

Kublickiene, Karolina http://orcid.org/0000-0002-4841-6836
,
Funding

Funding for this research was provided by:

vetenskapsrådet (2018-00932)

njurfonden

hjärt-lungfonden (20160384)

“la caixa” foundation (100010434)

canadian institutes of health research (GNP161904)

austrian science fund (FWF, I4209)

novo nordisk postdoctoral fellowship

scientific independence of young researcher program of the italian ministry of university (RBSI14HNVT)

Karolinska Institute
License Information

Text and Data Mining valid from 2021-09-15

Version of Record valid from 2021-09-15
More Information

Article History

Received: 28 June 2021

Accepted: 29 August 2021

First Online: 15 September 2021

Declarations

:

: The Regional Ethical Committee (EPN), Stockholm, Sweden, approved the study protocols, which were performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all subjects involved in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below